Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 2001 Feb 15;354(Pt 1):1–7. doi: 10.1042/0264-6021:3540001

Hydrolysis of platelet-activating factor by human serum paraoxonase.

L Rodrigo 1, B Mackness 1, P N Durrington 1, A Hernandez 1, M I Mackness 1
PMCID: PMC1221621  PMID: 11171072

Abstract

Human serum paraoxonase (human PON1) has been shown to be important in the metabolism of phospholipid and cholesteryl ester hydroperoxides, thereby preventing the oxidation of low-density lipoprotein (LDL) and retarding atherogenesis. However, the exact substrate specificity of PON1 has not been established. In the present study we show that purified PON1 hydrolyses platelet-activating factor (PAF). We could find no evidence for contamination of our preparation with authentic platelet-activating-factor acetylhydrolase (PAFAH) by immunoblotting with a PAFAH monoclonal antibody or by sequencing the purified protein. In addition the specific PAFAH inhibitor SB-222657 did not affect the ability of PON1 to hydrolyse PAF (30.1+/-2.8 micromol/min per mg of protein with no inhibitor; 31.4+/-2.2 micromol/min per mg of protein with 100 nM inhibitor) or phenyl acetate (242.6+/-30.8 versus 240.8+/-31.5 micromol/min per mg of protein with and without inhibitor respectively). SB-222657 was also unable to inhibit PAF hydrolysis by isolated human high-density lipoprotein (HDL), but completely abolished the activity of human LDL. Ostrich (Struthio camelus) HDL, which does not contain PON1, was unable to hydrolyse PAF. These data provide evidence that PON1 may limit the action of this bioactive pro-inflammatory phospholipid.

Full Text

The Full Text of this article is available as a PDF (174.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiyama M., Sugatani J., Suzuki T., Suzuki Y., Miwa M. Identification of a major PAF acetylhydrolase in human serum/plasma as a 43 kDa glycoprotein containing about 9 kDa asparagine-conjugated sugar chain(s). J Biochem. 1998 May;123(5):786–789. doi: 10.1093/oxfordjournals.jbchem.a022005. [DOI] [PubMed] [Google Scholar]
  2. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., Erogul J., Hsu C., Dunlop C., La Du B. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol. 1998 Oct;18(10):1617–1624. doi: 10.1161/01.atv.18.10.1617. [DOI] [PubMed] [Google Scholar]
  3. Biggadike K., Angell R. M., Burgess C. M., Farrell R. M., Hancock A. P., Harker A. J., Irving W. R., Ioannou C., Procopiou P. A., Shaw R. E. Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism. J Med Chem. 2000 Jan 13;43(1):19–21. doi: 10.1021/jm990436t. [DOI] [PubMed] [Google Scholar]
  4. Blatter Garin M. C., Abbott C., Messmer S., Mackness M., Durrington P., Pometta D., James R. W. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J. 1994 Dec 1;304(Pt 2):549–554. doi: 10.1042/bj3040549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Blatter M. C., James R. W., Messmer S., Barja F., Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem. 1993 Feb 1;211(3):871–879. doi: 10.1111/j.1432-1033.1993.tb17620.x. [DOI] [PubMed] [Google Scholar]
  6. Cao H., Girard-Globa A., Berthezene F., Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-->R genetic polymorphism. J Lipid Res. 1999 Jan;40(1):133–139. [PubMed] [Google Scholar]
  7. Evangelou A. M. Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. Prostaglandins Leukot Essent Fatty Acids. 1994 Jan;50(1):1–28. doi: 10.1016/0952-3278(94)90101-5. [DOI] [PubMed] [Google Scholar]
  8. Gan K. N., Smolen A., Eckerson H. W., La Du B. N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos. 1991 Jan-Feb;19(1):100–106. [PubMed] [Google Scholar]
  9. Hassett C., Richter R. J., Humbert R., Chapline C., Crabb J. W., Omiecinski C. J., Furlong C. E. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry. 1991 Oct 22;30(42):10141–10149. doi: 10.1021/bi00106a010. [DOI] [PubMed] [Google Scholar]
  10. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem. 2000 Feb 11;275(6):3957–3962. doi: 10.1074/jbc.275.6.3957. [DOI] [PubMed] [Google Scholar]
  11. Kuo C. L., La Du B. N. Comparison of purified human and rabbit serum paraoxonases. Drug Metab Dispos. 1995 Sep;23(9):935–944. [PubMed] [Google Scholar]
  12. La Du B. N., Eckerson H. W. The polymorphic paraoxonase/arylesterase isozymes of human serum. Fed Proc. 1984 May 15;43(8):2338–2341. [PubMed] [Google Scholar]
  13. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  14. Lee C., Sigari F., Segrado T., Hörkkö S., Hama S., Subbaiah P. V., Miwa M., Navab M., Witztum J. L., Reaven P. D. All ApoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase. Arterioscler Thromb Vasc Biol. 1999 Jun;19(6):1437–1446. doi: 10.1161/01.atv.19.6.1437. [DOI] [PubMed] [Google Scholar]
  15. MacPhee C. H., Moores K. E., Boyd H. F., Dhanak D., Ife R. J., Leach C. A., Leake D. S., Milliner K. J., Patterson R. A., Suckling K. E. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999 Mar 1;338(Pt 2):479–487. [PMC free article] [PubMed] [Google Scholar]
  16. Mackness M. I., Arrol S., Abbott C., Durrington P. N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993 Dec;104(1-2):129–135. doi: 10.1016/0021-9150(93)90183-u. [DOI] [PubMed] [Google Scholar]
  17. Mackness M. I., Arrol S., Durrington P. N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991 Jul 29;286(1-2):152–154. doi: 10.1016/0014-5793(91)80962-3. [DOI] [PubMed] [Google Scholar]
  18. Mackness M. I., Harty D., Bhatnagar D., Winocour P. H., Arrol S., Ishola M., Durrington P. N. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991 Feb;86(2-3):193–199. doi: 10.1016/0021-9150(91)90215-o. [DOI] [PubMed] [Google Scholar]
  19. Rodrigo L., Gil F., Hernandez A. F., Marina A., Vazquez J., Pla A. Purification and characterization of paraoxon hydrolase from rat liver. Biochem J. 1997 Feb 1;321(Pt 3):595–601. doi: 10.1042/bj3210595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Shih D. M., Gu L., Xia Y. R., Navab M., Li W. F., Hama S., Castellani L. W., Furlong C. E., Costa L. G., Fogelman A. M. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998 Jul 16;394(6690):284–287. doi: 10.1038/28406. [DOI] [PubMed] [Google Scholar]
  21. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk D. C. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985 Oct;150(1):76–85. doi: 10.1016/0003-2697(85)90442-7. [DOI] [PubMed] [Google Scholar]
  22. Stafforini D. M., McIntyre T. M., Carter M. E., Prescott S. M. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem. 1987 Mar 25;262(9):4215–4222. [PubMed] [Google Scholar]
  23. Stafforini D. M., Prescott S. M., McIntyre T. M. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J Biol Chem. 1987 Mar 25;262(9):4223–4230. [PubMed] [Google Scholar]
  24. Stafforini D. M., Zimmerman G. A., McIntyre T. M., Prescott S. M. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. Trans Assoc Am Physicians. 1992;105:44–63. [PubMed] [Google Scholar]
  25. Tew D. G., Southan C., Rice S. Q., Lawrence M. P., Li H., Boyd H. F., Moores K., Gloger I. S., Macphee C. H. Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler Thromb Vasc Biol. 1996 Apr;16(4):591–599. doi: 10.1161/01.atv.16.4.591. [DOI] [PubMed] [Google Scholar]
  26. Thomas T. C., McNamee M. G. Purification of membrane proteins. Methods Enzymol. 1990;182:499–520. doi: 10.1016/0076-6879(90)82040-9. [DOI] [PubMed] [Google Scholar]
  27. Tjoelker L. W., Wilder C., Eberhardt C., Stafforini D. M., Dietsch G., Schimpf B., Hooper S., Le Trong H., Cousens L. S., Zimmerman G. A. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature. 1995 Apr 6;374(6522):549–553. doi: 10.1038/374549a0. [DOI] [PubMed] [Google Scholar]
  28. Tselepis A. D., Dentan C., Karabina S. A., Chapman M. J., Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol. 1995 Oct;15(10):1764–1773. doi: 10.1161/01.atv.15.10.1764. [DOI] [PubMed] [Google Scholar]
  29. Watson A. D., Berliner J. A., Hama S. Y., La Du B. N., Faull K. F., Fogelman A. M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995 Dec;96(6):2882–2891. doi: 10.1172/JCI118359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Watson A. D., Navab M., Hama S. Y., Sevanian A., Prescott S. M., Stafforini D. M., McIntyre T. M., Du B. N., Fogelman A. M., Berliner J. A. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995 Feb;95(2):774–782. doi: 10.1172/JCI117726. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES